Discover how Moleculin Biotech advances Annamycin's Phase 3 trial for AML treatment, with key milestones planned through 2025.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback